Actalent’s Post

From navigating geopolitical conflicts to exploring the latest scientific breakthroughs, this year has been filled with both challenges and triumphs for the pharmaceutical industry. How will this year’s major milestones and innovative breakthroughs in drug development impact the year ahead? Watch Mike Ward, Head of Thought Leadership, Life Sciences & Healthcare, Clarivate, discuss the market performance of previous Drugs to Watch candidates - outlining their struggles, success and predictions for what it means for the industry in the coming year. Stay tuned for the 2024 edition of Drugs to Watch to discover upcoming blockbuster and breakthrough medicines: https://ow.ly/gLnx50QiilQ #drugdiscovery #healthcare #innovation #DrugstoWatch

Learn how to navigate the complexities of updated regulatory guidance and optimize your clinical trial planning, with our informative webinar, "Designing Quality into Clinical Trials: ICH E8 (R1)." Kathleen Wisemandle, CEO & Founder of Aspire to Grow, guides you through the proactive planning of clinical studies using Quality by Design and Critical to Quality factors assessments. Don't miss this opportunity to learn from an industry leader with over 30 years of experience in biotechnology and pharma. Watch on-demand now ⬇ https://okt.to/ImVgYR #clinicaltrials #ICHguidelines #pharmaindustry

Shrikanth P and Shanthakumar GS in the Dec 2023 issue of Pharma Times, present an interesting article on Intellectual Property: Growing Significance in Biomedical Industries. #intellectualproperty #biomedicalindustry #pharma #pharmatimes

It's amazing to think over 5,000 to 10,000 compounds are tested before making it into the hands of a patient! Enjoyed working on this video with my team, please give it a watch and learn about the complexities of bringing a new drug to market! #Pharma #DrugDevelopment #Video #ContentMarketing

"Optimizing the FDA’s Project Optimus: opportunities and challenges" by Rodney and Banerji examines the FDA's Project Optimus, focusing on streamlining drug reviews. The article discusses opportunities and challenges, particularly for new drug development companies like us that addresses unmet medical needs. Article link: https://lnkd.in/gUef_mnf #DrugDevelopment #RegulatoryAffairs #Biotech #PharmaceuticalIndustry

📣 Today I have joined to the EMA’s training webinar on Simultaneous National Scientific Advice (SNSA). This initiative is part of the EU Innovation Network roadmap between the EMA and the Heads of Medicines Agencies (HMA) to improve the regulatory support innovative medicines. 💡 It has been an interesting session where some of the leading NCAs for this initiative have shared: - Opportunities of carrying out a SNSA. - The main challenges after phase 1 and 2 pilot phase. - The process and procedures of the SNSA. - Some tips and learnings of the pilot phases. I highly recommend to all of you dedicated to #pharmaceuticalregulatoryaffairs in the EU to recover the video recording that will be published in some weeks (typically takes up to 60 days). The Q&A blocks, very illustrative also. #pharmaceuticalregulatory #ema #hma

Ancillare’s industry-shaping model navigates the complexities of the Clinical Trial Ancillary Supply Chain to reduce both the overall cost and cycle time of clinical trials, and greatly improve operational efficiency across all levels of the value chain. Contact us today to find out more https://lnkd.in/db8hxSun #ancillarysupply #ancillarysupplies #clincialtrials #biotech #pharma #supplychainmanagement